CLDN6 and neoplasm: Therapy proved most effective when directed against truly tumor-specific antigens such as EGFRvIII or CLDN6, or when CAR-T cell activation could be selectively triggered by cancer cells exhibiting higher expression levels of tumor-associated antigens like CLDN18.2 or GD-2 compared to normal tissues.